Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

<p>Antitumor activity of larotrectinib in tumors harboring <em>NTRK&nbsp;</em>gene fusions: a short review on the current evidence</p>
Biagio Ricciuti, Carlo Genova, Lucio Crinó, et al.
OncoTargets and Therapy (2019) Vol. Volume 12, pp. 3171-3179
Open Access | Times Cited: 42

Showing 1-25 of 42 citing articles:

Targeting apoptosis in cancer therapy
Benedito A. Carneiro, Wafik S. El‐Deiry
Nature Reviews Clinical Oncology (2020) Vol. 17, Iss. 7, pp. 395-417
Open Access | Times Cited: 1894
Clinical management of metastatic colorectal cancer in the era of precision medicine
Fortunato Ciardiello, Davide Ciardiello, Giulia Martini, et al.
CA A Cancer Journal for Clinicians (2022) Vol. 72, Iss. 4, pp. 372-401
Open Access | Times Cited: 362
Application of Next Generation Sequencing in Laboratory Medicine
Yiming Zhong, Feng Xu, Jinhua Wu, et al.
Annals of Laboratory Medicine (2020) Vol. 41, Iss. 1, pp. 25-43
Open Access | Times Cited: 160
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma
Giuseppe Lamberti, Elisa Andrini, Monia Sisi, et al.
Critical Reviews in Oncology/Hematology (2020) Vol. 156, pp. 103119-103119
Closed Access | Times Cited: 123
NTRK Fusions in Central Nervous System Tumors: A Rare, but Worthy Target
Alessandro Gambella, Rebecca Senetta, Giammarco Collemi, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 3, pp. 753-753
Open Access | Times Cited: 93
A review of NTRK fusions in cancer
Cristina Alexandra Manea, Dumitru Cristinel Badiu, Ioan Cristian Ploscaru, et al.
Annals of Medicine and Surgery (2022) Vol. 79
Open Access | Times Cited: 59
The Future of Precision Oncology
Stuart L. Rulten, Richard Grose, Susanne A. Gatz, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 16, pp. 12613-12613
Open Access | Times Cited: 23
Pan‐Trk immunohistochemistry is a sensitive and specific ancillary tool for diagnosing secretory carcinoma of the salivary gland and detecting ETV6–NTRK3 fusion
Bin Xu, Mohamed Rizwan Haroon Al Rasheed, Cristina R. Antonescu, et al.
Histopathology (2019) Vol. 76, Iss. 3, pp. 375-382
Open Access | Times Cited: 64
ESR1 fusions and therapeutic resistance in metastatic breast cancer
Zsuzsanna Nagy, Rinath Jeselsohn
Frontiers in Oncology (2023) Vol. 12
Open Access | Times Cited: 20
Synthesis, anticancer evaluation, molecular docking and ADME study of novel pyrido[4ʹ,3ʹ:3,4]pyrazolo[1,5-a]pyrimidines as potential tropomyosin receptor kinase A (TrKA) inhibitors
Nadia H. Metwally, Emad Abdullah Deeb, Ibrahim Walid Hasani
BMC Chemistry (2024) Vol. 18, Iss. 1
Open Access | Times Cited: 5
Roles of TrkC Signaling in the Regulation of Tumorigenicity and Metastasis of Cancer
Wook Jin
Cancers (2020) Vol. 12, Iss. 1, pp. 147-147
Open Access | Times Cited: 36
Green nanomedicine: the path to the next generation of nanomaterials for diagnosing brain tumors and therapeutics?
Ebrahim Mostafavi, David Medina-Cruz, Ada Vernet-Crua, et al.
Expert Opinion on Drug Delivery (2020) Vol. 18, Iss. 6, pp. 715-736
Closed Access | Times Cited: 30
Precision nanomedicine to treat non-small cell lung cancer
Akanksha Dessai, Usha Y. Nayak, Yogendra Nayak
Life Sciences (2024) Vol. 346, pp. 122614-122614
Open Access | Times Cited: 3
Immunohistochemistry as a screening tool for NTRK gene fusions: results of a first Belgian ring trial
Koen De Winne, Laure Sorber, Suzan Lambin, et al.
Virchows Archiv (2020) Vol. 478, Iss. 2, pp. 283-291
Open Access | Times Cited: 27
Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives
Carlo Genova, Giovanni Rossi, Marco Tagliamento, et al.
Expert Review of Respiratory Medicine (2020) Vol. 14, Iss. 4, pp. 367-383
Closed Access | Times Cited: 24
Gastrointestinal stromal tumors – Summary of mutational status of the primary/secondary KIT/PDGFRA mutations, BRAF mutations and SDH defects
Alena Kalfusova, Zdeněk Linke, Markéta Kalinová, et al.
Pathology - Research and Practice (2019) Vol. 215, Iss. 12, pp. 152708-152708
Closed Access | Times Cited: 24
Recent Research Progress of Chiral Small Molecular Antitumor-Targeted Drugs Approved by the FDA From 2011 to 2019
Xuetong Chu, Yizhi Bu, Xiaoping Yang
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 19
Design, synthesis, in-vitro and in-silico anticancer studies on amide derivatives of 1,3,4-oxadiazole-isoxazol-pyridine-benzimidazole
Eeduri Ramya Devi, Dasari Sravani, Ali G. Alkhathami, et al.
Chemical Papers (2024)
Closed Access | Times Cited: 2
NTRK fusions in colorectal cancer: clinical meaning and future perspective
Margherita Ratti, Giulia Grizzi, Rodolfo Passalacqua, et al.
Expert Opinion on Therapeutic Targets (2021) Vol. 25, Iss. 8, pp. 677-683
Closed Access | Times Cited: 16
Unique Genomic Alterations of Cerebrospinal Fluid Cell-Free DNA Are Critical for Targeted Therapy of Non-Small Cell Lung Cancer With Leptomeningeal Metastasis
Yongsheng Wang, Feng Jiang, Ruixue Xia, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 15
Nefarious NTRK oncogenic fusions in pediatric sarcomas: Too many to Trk
Megha R. Aepala, Malalage N. Peiris, Zian Jiang, et al.
Cytokine & Growth Factor Reviews (2022) Vol. 68, pp. 93-106
Open Access | Times Cited: 9
Metastatic Colorectal Cancer: Therapeutic Options for Treating Refractory Disease
Ambica Parmar, Kelvin Chan, Y.J. Ko
Current Oncology (2019) Vol. 26, Iss. 11, pp. 24-32
Open Access | Times Cited: 14
Precision medicine and its implementation in patients with NTRK fusion genes: perspective from developing countries
Andrés F. Cardona, Óscar Arrieta, Alejandro Ruíz-Patiño, et al.
Therapeutic Advances in Respiratory Disease (2020) Vol. 14
Open Access | Times Cited: 13
Locally Recurrent Secretory Carcinoma of the Breast with NTRK3 Gene Fusion
Lindsey Mortensen, Zehra Ordulu, Ibiayi Dagogo‐Jack, et al.
The Oncologist (2021) Vol. 26, Iss. 10, pp. 818-824
Open Access | Times Cited: 11
Larotrectinib followed by selitrectinib in a novelDCTN1–NTRK1fusion undifferentiated pleomorphic sarcoma
Xue Na Goh, Michaela Su-Fern Seng, Amos Hong Pheng Loh, et al.
Journal of Oncology Pharmacy Practice (2020) Vol. 27, Iss. 2, pp. 485-489
Closed Access | Times Cited: 11
Page 1 - Next Page

Scroll to top